These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 33564854)

  • 1. High susceptibility to zoliflodacin and conserved target (GyrB) for zoliflodacin among 1209 consecutive clinical Neisseria gonorrhoeae isolates from 25 European countries, 2018.
    Unemo M; Ahlstrand J; Sánchez-Busó L; Day M; Aanensen D; Golparian D; Jacobsson S; Cole MJ;
    J Antimicrob Chemother; 2021 Apr; 76(5):1221-1228. PubMed ID: 33564854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High in vitro susceptibility to the novel spiropyrimidinetrione ETX0914 (AZD0914) among 873 contemporary clinical Neisseria gonorrhoeae isolates from 21 European countries from 2012 to 2014.
    Unemo M; Ringlander J; Wiggins C; Fredlund H; Jacobsson S; Cole M
    Antimicrob Agents Chemother; 2015 Sep; 59(9):5220-5. PubMed ID: 26077246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Significant increase in azithromycin "resistance" and susceptibility to ceftriaxone and cefixime in Neisseria gonorrhoeae isolates in 26 European countries, 2019.
    Day MJ; Jacobsson S; Spiteri G; Kulishev C; Sajedi N; Woodford N; Blumel B; van der Werf MJ; Amato-Gauci AJ; Unemo M; Cole MJ;
    BMC Infect Dis; 2022 Jun; 22(1):524. PubMed ID: 35672671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Susceptibility Trends of Zoliflodacin against Multidrug-Resistant
    Le W; Su X; Lou X; Li X; Gong X; Wang B; Genco CA; Mueller JP; Rice PA
    Antimicrob Agents Chemother; 2021 Feb; 65(3):. PubMed ID: 33318010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stably high azithromycin resistance and decreasing ceftriaxone susceptibility in Neisseria gonorrhoeae in 25 European countries, 2016.
    Day MJ; Spiteri G; Jacobsson S; Woodford N; Amato-Gauci AJ; Cole MJ; Unemo M;
    BMC Infect Dis; 2018 Dec; 18(1):609. PubMed ID: 30509194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro antimicrobial combination testing of and evolution of resistance to the first-in-class spiropyrimidinetrione zoliflodacin combined with six therapeutically relevant antimicrobials for Neisseria gonorrhoeae.
    Foerster S; Drusano G; Golparian D; Neely M; Piddock LJV; Alirol E; Unemo M
    J Antimicrob Chemother; 2019 Dec; 74(12):3521-3529. PubMed ID: 31730160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neisseria gonorrhoeae diagnostic escape from a gyrA-based test for ciprofloxacin susceptibility and the effect on zoliflodacin resistance: a bacterial genetics and experimental evolution study.
    Rubin DH; Mortimer TD; Grad YH
    Lancet Microbe; 2023 Apr; 4(4):e247-e254. PubMed ID: 36868257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GyrB in silico mining in 27 151 global gonococcal genomes from 1928-2021 combined with zoliflodacin in vitro testing of 71 international gonococcal isolates with different GyrB, ParC and ParE substitutions confirms high susceptibility.
    Golparian D; Jacobsson S; Sánchez-Busó L; Bazzo ML; Lan PT; Galarza P; Ohnishi M; Unemo M
    J Antimicrob Chemother; 2022 Dec; 78(1):150-154. PubMed ID: 36308328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overall Low Extended-Spectrum Cephalosporin Resistance but high Azithromycin Resistance in Neisseria gonorrhoeae in 24 European Countries, 2015.
    Cole MJ; Spiteri G; Jacobsson S; Woodford N; Tripodo F; Amato-Gauci AJ; Unemo M;
    BMC Infect Dis; 2017 Sep; 17(1):617. PubMed ID: 28893203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gonococcal resistance to zoliflodacin could emerge via transformation from commensal Neisseria species. An in-vitro transformation study.
    Abdellati S; Laumen JGE; de Block T; De Baetselier I; Van Den Bossche D; Van Dijck C; Manoharan-Basil SS; Kenyon C
    Sci Rep; 2024 Jan; 14(1):1179. PubMed ID: 38216602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Europe-wide expansion and eradication of multidrug-resistant Neisseria gonorrhoeae lineages: a genomic surveillance study.
    Sánchez-Busó L; Cole MJ; Spiteri G; Day M; Jacobsson S; Golparian D; Sajedi N; Yeats CA; Abudahab K; Underwood A; Bluemel B; Aanensen DM; Unemo M;
    Lancet Microbe; 2022 Jun; 3(6):e452-e463. PubMed ID: 35659907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Using a public database of Neisseria gonorrhoeae genomes to detect mutations associated with zoliflodacin resistance.
    Adamson PC; Lin EY; Ha SM; Klausner JD
    J Antimicrob Chemother; 2021 Oct; 76(11):2847-2849. PubMed ID: 34324655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antimicrobial-resistant Neisseria gonorrhoeae in Europe in 2020 compared with in 2013 and 2018: a retrospective genomic surveillance study.
    Golparian D; Cole MJ; Sánchez-Busó L; Day M; Jacobsson S; Uthayakumaran T; Abad R; Bercot B; Caugant DA; Heuer D; Jansen K; Pleininger S; Stefanelli P; Aanensen DM; Bluemel B; Unemo M;
    Lancet Microbe; 2024 May; 5(5):e478-e488. PubMed ID: 38614111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging cephalosporin and multidrug-resistant gonorrhoea in Europe.
    Cole MJ; Spiteri G; Chisholm SA; Hoffmann S; Ison CA; Unemo M; Van de Laar M
    Euro Surveill; 2014 Nov; 19(45):20955. PubMed ID: 25411689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The European gonococcal antimicrobial surveillance programme (Euro-GASP) appropriately reflects the antimicrobial resistance situation for Neisseria gonorrhoeae in the European Union/European Economic Area.
    Cole MJ; Quinten C; Jacobsson S; Day M; Amato-Gauci AJ; Woodford N; Spiteri G; Unemo M;
    BMC Infect Dis; 2019 Dec; 19(1):1040. PubMed ID: 31822275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retrospective analysis of antimicrobial susceptibility trends (2000-2009) in Neisseria gonorrhoeae isolates from countries in Latin America and the Caribbean shows evolving resistance to ciprofloxacin, azithromycin and decreased susceptibility to ceftriaxone.
    Starnino S; ; Galarza P; Carvallo ME; Benzaken AS; Ballesteros AM; Cruz OM; Hernandez AL; Carbajal JL; Borthagaray G; Payares D; Dillon JA
    Sex Transm Dis; 2012 Oct; 39(10):813-21. PubMed ID: 23001269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimicrobial resistance in Neisseria gonorrhoeae isolates and gonorrhoea treatment in the Republic of Belarus, Eastern Europe, 2009-2019.
    Aniskevich A; Shimanskaya I; Boiko I; Golubovskaya T; Golparian D; Stanislavova I; Jacobsson S; Adaskevich A; Unemo M
    BMC Infect Dis; 2021 Jun; 21(1):520. PubMed ID: 34078300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent dynamics in Neisseria gonorrhoeae genomic epidemiology in Brazil: antimicrobial resistance and genomic lineages in 2017-20 compared to 2015-16.
    Golparian D; Bazzo ML; Ahlstrand J; Schörner MA; Gaspar PC; de Melo Machado H; Martins JM; Bigolin A; Ramos MC; Ferreira WA; Pereira GFM; Miranda AE; Unemo M;
    J Antimicrob Chemother; 2024 May; 79(5):1081-1092. PubMed ID: 38517452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluating the potency of zoliflodacin against Helicobacter pylori: In vitro activity and conserved GyrB target.
    Liu J; Jia J; Shi T; Bai Y; Huang Y; Zeng L; Bi H
    Helicobacter; 2024; 29(2):e13075. PubMed ID: 38627919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of the novel oral antimicrobial SMT-571, with a new mechanism of action, against MDR and XDR Neisseria gonorrhoeae: future treatment option for gonorrhoea?
    Jacobsson S; Mason C; Khan N; Meo P; Unemo M
    J Antimicrob Chemother; 2019 Jun; 74(6):1591-1594. PubMed ID: 30778550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.